Yuzbasiyan-Gurkan V, Brewer G J, Abrams G D, Main B, Giacherio D
Department of Human Genetics, University of Michigan, Ann Arbor 48109.
J Lab Clin Med. 1989 Nov;114(5):520-6.
We noted a frequent increase in the serum enzymes amylase, lipase, and alkaline phosphatase in patients with Wilson's disease who are receiving zinc acetate therapy (25 or 50 mg elemental zinc three times daily). Typically, values are normal before the initiation of zinc therapy, increase to slightly above normal after a few weeks of therapy, and stabilize at the high normal range after approximately a year of treatment. Very large dosages of zinc (800 mg/day) produce even further elevation of serum lipase and amylase without the symptoms of pancreatitis. Pancreatic pathologic studies of a zinc-treated rat model receiving dosages equivalent to up to 25 times the effective dosage in a human being, which is based on milligrams of zinc per kilogram of body weight, reveal that no lesions are induced by zinc treatment in the pancreas. We interpret these findings to indicate that extended maintenance therapy with zinc does not pose a risk of pancreatic damage in patients with Wilson's disease.
我们注意到，接受醋酸锌治疗（每日三次，每次25或50毫克元素锌）的威尔逊病患者，其血清淀粉酶、脂肪酶和碱性磷酸酶常有升高。通常，锌治疗开始前这些值是正常的，治疗几周后升至略高于正常水平，治疗约一年后稳定在高正常范围。非常大剂量的锌（800毫克/天）会使血清脂肪酶和淀粉酶进一步升高，但无胰腺炎症状。对锌治疗的大鼠模型进行胰腺病理研究，给予相当于人类有效剂量25倍的剂量（基于每千克体重的锌毫克数），结果显示锌治疗未在胰腺诱发病变。我们将这些发现解释为，威尔逊病患者长期接受锌维持治疗不会有胰腺损伤风险。
